AIMS/HYPOTHESIS: Alterations in white adipose tissue (WAT) function, including changes in protein (adipokine) secretion and extracellular matrix (ECM) composition, promote an insulin-resistant state. We set out to identify novel adipokines regulated by body fat mass in human subcutaneous WAT with potential roles in adipose function. METHODS: Adipose transcriptome data and secretome profiles from conditions with increased/decreased WAT mass were combined. WAT donors were predominantly women. In vitro effects were assessed using recombinant protein. Results were confirmed by quantitative PCR/ELISA, metabolic assays and immunochemistry in human WAT and adipocytes. RESULTS: We identified a hitherto uncharacterised adipokine, semaphorin 3C (SEMA3C), the expression of which correlated significantly with body weight, insulin resistance (HOMA of insulin resistance [HOMAIR], and the rate constant for the insulin tolerance test [KITT]) and adipose tissue morphology (hypertrophy vs hyperplasia). SEMA3C was primarily found in mature adipocytes and had no direct effect on human adipocyte differentiation, lipolysis, glucose transport or the expression of β-oxidation genes. This could in part be explained by the significant downregulation of its cognate receptors during adipogenesis. In contrast, in pre-adipocytes, SEMA3C increased the production/secretion of several ECM components (fibronectin, elastin and collagen I) and matricellular factors (connective tissue growth factor, IL6 and transforming growth factor-β1). Furthermore, the expression of SEMA3C in human WAT correlated positively with the degree of fibrosis in WAT. CONCLUSIONS/ INTERPRETATION: SEMA3C is a novel adipokine regulated by weight changes. The correlation with WAT hypertrophy and fibrosis in vivo, as well as its effects on ECM production in human pre-adipocytes in vitro, together suggest that SEMA3C constitutes an adipocyte-derived paracrine signal that influences ECM composition and may play a pathophysiological role in human WAT.
AIMS/HYPOTHESIS: Alterations in white adipose tissue (WAT) function, including changes in protein (adipokine) secretion and extracellular matrix (ECM) composition, promote an insulin-resistant state. We set out to identify novel adipokines regulated by body fat mass in human subcutaneous WAT with potential roles in adipose function. METHODS: Adipose transcriptome data and secretome profiles from conditions with increased/decreased WAT mass were combined. WAT donors were predominantly women. In vitro effects were assessed using recombinant protein. Results were confirmed by quantitative PCR/ELISA, metabolic assays and immunochemistry in human WAT and adipocytes. RESULTS: We identified a hitherto uncharacterised adipokine, semaphorin 3C (SEMA3C), the expression of which correlated significantly with body weight, insulin resistance (HOMA of insulin resistance [HOMAIR], and the rate constant for the insulin tolerance test [KITT]) and adipose tissue morphology (hypertrophy vs hyperplasia). SEMA3C was primarily found in mature adipocytes and had no direct effect on human adipocyte differentiation, lipolysis, glucose transport or the expression of β-oxidation genes. This could in part be explained by the significant downregulation of its cognate receptors during adipogenesis. In contrast, in pre-adipocytes, SEMA3C increased the production/secretion of several ECM components (fibronectin, elastin and collagen I) and matricellular factors (connective tissue growth factor, IL6 and transforming growth factor-β1). Furthermore, the expression of SEMA3C in human WAT correlated positively with the degree of fibrosis in WAT. CONCLUSIONS/ INTERPRETATION:SEMA3C is a novel adipokine regulated by weight changes. The correlation with WAT hypertrophy and fibrosis in vivo, as well as its effects on ECM production in human pre-adipocytes in vitro, together suggest that SEMA3C constitutes an adipocyte-derived paracrine signal that influences ECM composition and may play a pathophysiological role in human WAT.
Authors: Peter Arner; Samuel Bernard; Mehran Salehpour; Göran Possnert; Jakob Liebl; Peter Steier; Bruce A Buchholz; Mats Eriksson; Erik Arner; Hans Hauner; Thomas Skurk; Mikael Rydén; Keith N Frayn; Kirsty L Spalding Journal: Nature Date: 2011-09-25 Impact factor: 49.962
Authors: Erik Arner; Pål O Westermark; Kirsty L Spalding; Tom Britton; Mikael Rydén; Jonas Frisén; Samuel Bernard; Peter Arner Journal: Diabetes Date: 2009-10-21 Impact factor: 9.461
Authors: Hui Gao; Niklas Mejhert; Jackie A Fretz; Erik Arner; Silvia Lorente-Cebrián; Anna Ehrlund; Karin Dahlman-Wright; Xiaowei Gong; Staffan Strömblad; Iyadh Douagi; Jurga Laurencikiene; Ingrid Dahlman; Carsten O Daub; Mikael Rydén; Mark C Horowitz; Peter Arner Journal: Cell Metab Date: 2014-05-22 Impact factor: 27.287
Authors: James E N Minchin; Catherine M Scahill; Nicole Staudt; Elisabeth M Busch-Nentwich; John F Rawls Journal: J Lipid Res Date: 2018-05-23 Impact factor: 5.922
Authors: Vanessa Pellegrinelli; Vivian J Peirce; Laura Howard; Samuel Virtue; Dénes Türei; Martina Senzacqua; Andrea Frontini; Jeffrey W Dalley; Antony R Horton; Guillaume Bidault; Ilenia Severi; Andrew Whittle; Kamal Rahmouni; Julio Saez-Rodriguez; Saverio Cinti; Alun M Davies; Antonio Vidal-Puig Journal: Nat Commun Date: 2018-11-26 Impact factor: 14.919
Authors: Juan R Acosta; Simon Joost; Kasper Karlsson; Anna Ehrlund; Xidan Li; Myriam Aouadi; Maria Kasper; Peter Arner; Mikael Rydén; Jurga Laurencikiene Journal: Stem Cell Res Ther Date: 2017-11-07 Impact factor: 6.832